Capricor Therapeutics (CAPR) provides regulatory update on deramiocel BLA following FDA review of hope-3 topline data

Capricor Therapeutics' update indicates the FDA's request for the full clinical study report related to their BLA review, as well as their expected timeline for submitting updates in February 2026.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

US Bancorp (USB) CEO says 90% of clients will see a detrimental impact from the rate cap on credit cards

Danish PM says they will not abandon Greenland and proposing a more permanent presence in the Artic in line with Baltic Sentry; on EU "trade bazooka", thinks it's a very bad idea with a trade war among allies and hope to avoid measures such as the bazooka

Capricor Therapeutics (CAPR) provides regulatory update on deramiocel BLA following FDA review of hope-3 topline data

Japanese Finance Minister reiterates that FX intervention remains an option and they are not conducting expansionary policy

Palantir (PLTR) announces a deal with Hyundai (005380 SK) worth hundreds of millions of dollars, with the Co.'s CEO adding that he's highly bullish on the Korean market, via Reuters

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • FDA requests hope-3 clinical study report for BLA review.
  • Co. expects to submit BLA updates in February 2026.
  • Expects to submit updates to BLA in February 2026 to support continued FDA review.
  • FDA requests full hope-3 report to address CRL.
Context

This is significant as it suggests the FDA is still engaged in the review process but requires additional data to proceed, potentially impacting the stock's volatility and investor sentiment.

Related headlines

The whole workspace, free to try.

Try it free